Long-term survival with stereotactic radiosurgery and 100+ cycles of Keytruda in a patient with brain metastases from melanoma - Scorecard - MDSpire

Long-term survival with stereotactic radiosurgery and 100+ cycles of Keytruda in a patient with brain metastases from melanoma

  • By

  • Darrah Sheehan

  • Kimball Sheehan

  • Yuki Shinya

  • Camilo E. Fadul

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Sustained Survival in a Melanoma Patient with Brain Metastases Treated with Stereotactic Radiosurgery and Over 100 Doses of Keytruda

At a Glance

CategoryDetail
Condition
Key MechanismsStereotactic radiosurgery (SRS) and immune checkpoint inhibition (pembrolizumab) as per source.
Target Population
Care Setting

Key Highlights

  • SRS provides effective focal control for intracranial lesions in melanoma.
  • Pembrolizumab demonstrated durable extracranial disease control.
  • Iterative SRS can complement immunotherapy for intracranial progression.
  • No new intracranial metastases detected during prolonged follow-up.

Guideline-Based Recommendations

Diagnosis

  • Regular neuro-imaging for surveillance of brain metastases.

Management

  • Use SRS for symptomatic or dominant lesions in the brain.

Monitoring & Follow-up

  • Close neuro-imaging follow-up during systemic therapy.

Risks

  • Potential for new intracranial metastases despite treatment.

Patient & Prescribing Data

Elderly patients with advanced melanoma and brain metastases.

Individualized treatment based on age and systemic disease status.

Clinical Best Practices

  • Integrate SRS and immunotherapy in treatment plans.
  • Employ a stepwise approach with serial imaging.

Related Resources & Content

Original Source(s)

Long-term survival with stereotactic radiosurgery and 100+ cycles of Keytruda in a patient with brain metastases from melanoma

  • by Darrah Sheehan, Kimball Sheehan, Yuki Shinya, Camilo E. Fadul

  • June 18, 2026

Related Content

Editorial: The role of immune and stromal mediators in the formation of pre-metastatic and metastatic niches: the gateway to metastasis

2026 AACR Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis